Travis Rutland, MD
Gastroenterology · Dothan, ALNPI 1518922087
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $237,267 of the $302,058 with a category attached, or 78.6%. 46 manufacturers reported payments, led by Johnson & Johnson at 40.8% of the total. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 845 payments — averaging $357.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$123K
- Phathom Pharmaceuticals, Inc.$62K
- Janssen Scientific Affairs, LLC$48K
- Sanofi$22K
- Pfizer$18K
- E.r. Squibb & Sons, L.L.C.$7K
- plus $22K from 40 others
Across 77 payments — averaging $3241.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$136K
- AbbVie$37K
- E.r. Squibb & Sons, L.L.C.$34K
- Janssen Research & Development, LLC$24K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Ironwood Pharmaceuticals, Inc$9K
What the payments were for
- Consulting fees$4,3001%
- Speaking & faculty fees$237,26779%
- Travel & lodging$42,09414%
- Food & beverage$18,2636%
- Education$1070%
- Gifts$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$144,828
- Tremfya$101,634
- VOQUEZNA$61,055
- DUPIXENT$28,041
- XELJANZ$17,849
- ZEPOSIA$6,800
- Alinia$6,337
- TRUFREEZE$2,140
- EVIS EXERA lll COLONOVIDEOSCOPE$263
- Rinvoq$241
- DiLumen EZ1, 103 cm$146
- DiLumen EZ1, 130 cm$146
- INTERSTIM$128
- Skyrizi$120
- IBSRELA$113
How this compares
$302,058 in reported general payments places this provider in the 95th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 96 | $2,702,375 |
| LinzessLinaclotide | 416 | $348,148 |
| CreonLipase/Protease/Amylase | 97 | $280,117 |
| Humira(Cf) PenAdalimumab | 23 | $185,427 |
| XifaxanRifaximin | 59 | $175,575 |
| ZenpepLipase/Protease/Amylase | 43 | $147,700 |
| TrulancePlecanatide | 147 | $112,425 |
| Humira PenAdalimumab | 12 | $81,740 |
| IbsrelaTenapanor Hcl | 34 | $77,870 |
| Dexlansoprazole DrDexlansoprazole | 260 | $60,695 |
| Alosetron Hcl | 35 | $22,106 |
| MovantikNaloxegol Oxalate | 30 | $20,536 |
| Pantoprazole Sodium | 1,651 | $15,611 |
| Lubiprostone | 108 | $13,671 |
| MotegrityPrucalopride Succinate | 19 | $12,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $123,322 | $2,702,37596 claims |
| AbbVieLinzess, Creon | $2,678 | $628,265513 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,052 | $288,000206 claims |
| Aimmune Therapeutics, Inc.Zenpep | $75 | $147,70043 claims |
| Ardelyx, Inc.Ibsrela | $677 | $77,87034 claims |
| Redhill Biopharma Inc.Movantik | $51 | $20,53630 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $628 | $18,71030 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $176 | $3,87227 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $54 | $2,60715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Dothan
- Paul LambDothan$58K
- Samuel TarwaterDothan$12K
- George NelsonDothan$11K
- Scott SarrelsDothan$10K
- Robert AlbaresDothan$9K
- William McLaughlinDothan$8K
- Robert ShafferBirmingham$1M
- Jack DipalmaMobile$903K
- Phillip HendersonMobile$462K
- Viplove SenadhiMontgomery$282K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.